L-3 Communications (LLL) announced that its Security and Detection Systems division has been "awarded an indefinite-delivery/indefinite-quantity contract by the TSA to supply medium-speed explosives detection systems. This five-year acquisition program has a rev potential of $549.6 mln for L-3."
StemCells (STEM) announced it has partnered with R Biomedical to "develop and commercialize reagents for Human iPS Cell Research: The first product under the partnership, an 'ultra-primary' human fibroblast cell line from which researchers can generate iPS cell lines, was launched today under the SC Proven brand."
Stewart Enterprises (STEI) got a good review from Zachs Equity Research. "STEI is a good pick for investors seeking both growth and income, based on its solid third-quarter results, steady dividend yield and long-term earnings growth projection of 10.0%."
No comments:
Post a Comment